AREC vs. REDX, TRX, POLB, C4XD, HEMO, ONC, ETX, SBTX, OBD, and DEST
Should you be buying Arecor Therapeutics stock or one of its competitors? The main competitors of Arecor Therapeutics include Redx Pharma (REDX), Tissue Regenix Group (TRX), Poolbeg Pharma (POLB), C4X Discovery (C4XD), Hemogenyx Pharmaceuticals (HEMO), Oncimmune (ONC), e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Oxford BioDynamics (OBD), and Destiny Pharma (DEST). These companies are all part of the "biotechnology" industry.
Arecor Therapeutics (LON:AREC) and Redx Pharma (LON:REDX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.
Arecor Therapeutics has a beta of -0.22, indicating that its share price is 122% less volatile than the S&P 500. Comparatively, Redx Pharma has a beta of -0.53, indicating that its share price is 153% less volatile than the S&P 500.
54.2% of Arecor Therapeutics shares are owned by institutional investors. Comparatively, 72.7% of Redx Pharma shares are owned by institutional investors. 31.3% of Arecor Therapeutics shares are owned by company insiders. Comparatively, 18.2% of Redx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Redx Pharma has a net margin of 0.00% compared to Arecor Therapeutics' net margin of -278.81%. Arecor Therapeutics' return on equity of -67.81% beat Redx Pharma's return on equity.
Redx Pharma received 153 more outperform votes than Arecor Therapeutics when rated by MarketBeat users.
In the previous week, Redx Pharma had 2 more articles in the media than Arecor Therapeutics. MarketBeat recorded 4 mentions for Redx Pharma and 2 mentions for Arecor Therapeutics. Redx Pharma's average media sentiment score of 1.45 beat Arecor Therapeutics' score of 0.24 indicating that Redx Pharma is being referred to more favorably in the news media.
Arecor Therapeutics has higher earnings, but lower revenue than Redx Pharma. Arecor Therapeutics is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Redx Pharma beats Arecor Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Arecor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AREC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arecor Therapeutics Competitors List
Related Companies and Tools
